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Not many years ago the main purpose of "com
plement" seemed to be to drill holes in sheep eryth
rocytes. In the classic experiment which was part of
every medical student's microbiology laboratory ex
perience, a magic stuff called complement, somewhat
mysteriously obtained from guinea pigs. was either
"fixed" or not "fixed" and the sheep cells either not
lysed or lysed accordingly.'That was about all there
was to know about complement, and all one needed
to know.
Today the term "complement" embodies a
group of plasma proteins which react in a complex
sequence to mediate a variety of inflammatory ef
fects, including changes in vascular permeability, the
attraction of polymorphonuclear or mononuclear
leukocytes, the enhancement of phagocytosis. and
damage to cell membranes and osmotic lysis such as
the sheep erythrocyte suffered in the complement fix
ation test. These complement proteins rival the in
trinsic coagulation scheme in complexity and re
semble it in mechanism, that is. the complement
proteins normally circulate in the plasma in an in
active or precursor form, and when appropriately
stimulated, usually during an immunologic reaction,
become transformed into active enzymes, or pro
teases. These proteases act upon their natural sub
strates (other members of the complement system) in
an orderly and predetermined sequence of limited
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proteolytic reactions which are often compared to a
"cascade" or "waterfall." Cleavage of one com
ponent leads to the activation of the next component,
and so forth. Natural inhibitors or inactivators also
present in plasma serve to modulate or damp this
cascade system and prevent its getting out of control.
In fact, congenital deficiency of one of these inhib
itors, the Cl Inhibitor, leads to uncontrolled activa
tion of the system and recurrent swelling of the sub
epithelial tissues of the skin, respiratory and
gastrointestinal tracts.2

Biochemical Pathways.•-•

Two pathways for activation. the classic and
alternative (properdin ), initiate the terminal attack
sequence which elaborates most of the biologic activi
ties associated with complement. The classic pathway
is activated by immune complexes containing IgG or
lgM immunoglobulins and their associated antigens.
The properdin pathway is activated by certain kinds
of repeating polysaccharides such as pneumococcal
polysaccharide, or the bacterial lipopolysaccharide of
gram-negative endotoxin: immune complexes con
taining lgA may also activate the properdin system.
Regardless of which pathway is activated, both
result in the cleavage of C3 and CS. Peptides released
from these components, C3a and CSa, are anaphy
latoxins capable of releasing histamine from mast
cells and thereby influencing local vascular per
meability. CSa also releases lysosomal enzymes and
presumably other granular contents from poly
morphonuclear leukocytes. Both C3a and CSa have
chemotactic activity as well, the latter being more
active in most systems: the trimolecular complex
formed from CS, C6, and C7 is also chemotactic.
Immune complexes to which complement, especially
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C3b, has become bound adhere to poly
morphonuclear neutrophils, mononuclear cells and
B-lymphocytes. Although the functional significance
of these binding phenomena is not yet entirely clear,
enhanced phagocytosis by mononuclear or poly
morphonuclear cells is certainly one consequence.
Formation of a multimolecular complex involving
CS, C6, C7, C8, and C9 leads to the membrane dam
age and osmotic lysis which have become the hall
marks of complement activation.
Metabolism of Complement Proteins.

One result of the proteolysis of the complement
proteins during their activation is that they sub
sequently become recognizable as "altered" or "for
eign" by the body and are rapidly cleared from the
circulation. Although some compensatory increases
in synthesis may occur, the result is usually a fall in
plasma level. Thus, an ongoing immunologic event
(or disease) which is activating the complement sys
tem in vivo may be manifested as a fall in the serum
or plasma level of one or more of the complement
proteins. In reverse fashion, as the complement-acti
vating stimulus or disease abates, this may be paral
leled by a return towards normal in the complement
levels.
Determinations of Complement in the Clinical Pa
thology Laboratory.

In principle, there are two ways of measuring
complement: (I) by its activity in the reaction it ca
talyzes, for example, the total hemolytic complement
or CHSO, which measures the result of the interaction
of all nine of the classic complement components or
(2) by its antigenicity, as a protein in an immunoas
say which takes advantage of the complement pro
tein's capacity to react with monospecific antibody
directed against it. In practice, although total he
molytic complement or CHSO determinations are
available in some institutions, immunoassays (usually
radial immunodiffusion) are most frequently avail
able. Materials for these are offered in the form of
kits for use in the clinical pathology laboratory by a
number of commercial suppliers.
A few comments are in order about the radial
immunodiffusion determinations for complement
components available in most hospitals.
I) Radial immunodiffusion, by its very nature,
is not nearly as precise a determination as
most physicians have come to expect from
clinical laboratories. Under the best condi
tions, the coefficient of variation of the tesl. is
likely to be 8% or greater, more than twice

that of commonly available clinical chemistry
or hematologic procedures. Thus in inter
preting the results of the test, the physician
must take into account this reduced preci
sion, for example, a "fall" in C3 level from
I45 to I 30 mg/ I 00 ml from one day to the
next may reflect only laboratory variation.
2) There are no widely available standards, so
that considerable variation in absolute values
obtained by kits from different suppliers or
even in lots of kits from the same supplier
may be observed. This should not be a prob
lem if results are referred to a normal range
collected at the institution in which the test is
being performed, and if appropriate internal
standards, maintained at the institution, are
assayed in parallel with the test samples. If
the "normal ranges" provided with the kits
are accepted as verbatim, and if independent
checks of the performance of the kits are
neglected, then unreliable data may result.
3) As for other plasma proteins, the range of
normal for complement proteins is quite
broad, usually in the vicinity of± 50% of the
mean value for the population. Thus changes
in levels in a single patient over a period of
time may often be more helpful and easier to
interpret than are comparisons with some ab
solute range of normal. For example. a pa
tient with suspect systemic lupus erythema
tosus whose C4 level fell from 70 mg/ I 00 ml
to 30 mg/JOO ml within two weeks might be
cause for alarm, even though the latter value
was still "within the range of normal."
4) The most widely available test for a com
plement component (C3) is not necessarily
the most desirable. Its availability is directly
related to the fact that C3 is by far the most
plentiful of the complement components. the
easiest to purify. and therefore the easiest to
make antibody against for use in a radio
immunoassay. Measurements of C3 were
therefore widely available from commercial
sources several years in advance of measure
ments of other components. Most workers
would agree today, however, that measure
ments of C4 are likely to be more sensitive to
minor episodes of in vivo complement activa
tion. and that a good "routine" complement
screen would include measurements of C4,
C3, and possibly CHSO.
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5) The immunoassays do not distinguish be
tween native protein and that which has par
ticipated in complement activation and lost
its activity but not its immunogenicity. They
are reliable, therefore, only in instances in
which substantial amounts of cleaved, in
active protein would not be expected. Altered
complement proteins are cleared within a few
hours from the plasma space, and the finding
of altered inactive protein in plasma requires
special techniques to detect the small
amounts which are present. In contrast, how
ever, altered inactive protein may persist for
much longer times in joint spaces or pleural
spaces, so that radial immunodiffusion deter
minations of C3 or C4 in synovial or pleural
fluid are of very little value. Recent studies
have shown that measurements of C4 in cere
brospinal fluid are similarly of little diagnos
tic value with respect to the presence or ab
sence of central nervous system involvement
in systemic lupus erythematosus.
Clinical Significance.

Given the knowledge that the complement sys
tem may be activated in vivo by immunologic dis
eases, and that simple and reliable methods for mea
suring complement levels are now widely available,
how can the practitioner best use this information?
What are the diseases in which complement measure
ments are likely to be of help, either in diagnosis or in
following the course of the patient? The answer is
simple: any disease in which the physician suspects
that circulating immune complexes may be playing a
pathogenetic role. A few of them are listed in the Table.
Systemic lupus erythematosus is the disease
which is perhaps most commonly associated with
hypocomplementemia, but it is well to bear in mind
that other diseases in which circulating antigen-an-

TABLE
Diseases in which Complement Determinations May Provide Useful
Diagnostic or Therapeutic Information
Systemic lupus erythematosus
Rheumatoid arthritis (with systemic vasculitis)
Hypersensitivity angiitis
Angioedema
Glomerulonephritis
Subacute bacterial endocarditis
Hepatitis
Essential mixed cryoglobulinemia
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tibody complexes may be found may also give rise to
hypocomplementemia. Among these would be in
cluded any cause of "chronic antigenemia," for ex
ample, subacute bacterial endocarditis, hepatitis B
surface antigenemia, infected atrioventricular shunts,
recurrent gram-negative sepsis, recurrent viremias
such as dengue hemorrhagic fever, or recurrent para
sitemia, such as falciparum malaria. Other diseases of
unknown etiology may be associated with hypo
complementemia, such as essential mixed cryoglo
bulinemia, or certain kinds of nephritis (which in
contrast to all the diseases mentioned above which
are likely to have low C4, and sometimes low C3,
usually have only low C3, suggesting direct alterna
tive pathway activation). The symptom of "angioed
ema" is infrequently associated with hypocomple
mentemia, but a screening test should be done for C4,
which is low in almost all cases of hereditary angioed
ema. especially since very effective treatment for this
disease is now available.
In most instances in which hypocomplemen
temia is found in association with the disease, im
provements in complement levels are often early and
reliable indices that the disease is ameliorating either
spontaneously or as a result of therapy.
Thus, by applying his understanding of "com
plement fixation," obtained in the classical micro
biology laboratory experiment, to human diseases in
which "complement fixation" appears to be occur
ring in vivo, today's physician has achieved a useful
diagnostic tool and therapeutic index in the measure
ment of complement components in disease.
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